Does Rallies show 13F holders for REPL?

Yes. Rallies tracks hedge fund and 13F ownership data for REPL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is REPL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for REPL. It does not provide personalized investment advice.

REPL (Replimune Group, Inc.) Stock Analysis - Hedge Fund Holdings

Replimune Group, Inc. (REPL) is a publicly traded Healthcare sector company. As of May 21, 2026, REPL trades at $5.23 with a market cap of $413.69M and a P/E ratio of -1.65. REPL moved +9.57% today. Year to date, REPL is -38.72%; over the trailing twelve months it is -43.85%. Its 52-week range spans $1.50 to $17.00. Analyst consensus is sell with an average price target of $2.25. Rallies surfaces REPL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns REPL stock?

Hedge funds tracked by Rallies that own REPL include Redmile Group and Panagora Asset. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Replimune Group, Inc..

REPL Key Metrics

Key financial metrics for REPL
Metric	Value
Price	$5.23
Market Cap	$413.69M
P/E Ratio	-1.65
EPS	$-3.07
Dividend Yield	0.00%
52-Week High	$17.00
52-Week Low	$1.50
Volume	4.43K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-247.30M
Gross Margin	0.00%

Top Hedge Funds Holding REPL

Redmile Group holds 1.10M shares of REPL, changed +105.25% as of Dec 31, 2025.
Panagora Asset holds 181.28K shares of REPL, changed +117.77% as of Mar 31, 2026.

Latest REPL News

Replimune Presents 3-Year Survival and RP2 Phase 1 Safety Data at ASCO — Apr 27, 2026
Replimune Shares Plunge 64% After FDA Rejects RP1 Melanoma Therapy, Plans Layoffs — Apr 13, 2026
Replimune Shares Rally 43.6% as Loss Estimates Narrow for 2026-27 — Mar 10, 2026

Recent REPL Insider Trades

Xynos Konstantinos sold 14.02K (~$71.24K) on May 18, 2026.
Schwendenman Andrew sold 7.89K (~$40.10K) on May 18, 2026.
Sarchi Christopher sold 8.63K (~$43.82K) on May 18, 2026.

REPL Analyst Consensus

7 analysts cover REPL: 0 strong buy, 0 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is sell. Average price target: $2.25.

Common questions about REPL

Who owns REPL stock?: Hedge funds tracked by Rallies that own REPL include Redmile Group and Panagora Asset. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Replimune Group, Inc..
Does Rallies show 13F holders for REPL?: Yes. Rallies tracks hedge fund and 13F ownership data for REPL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is REPL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for REPL. It does not provide personalized investment advice.